Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · IEX Real-Time Price · USD
1.86
+0.09 (5.08%)
At close: Dec 29, 2023, 4:00 PM
1.79
-0.07 (-3.76%)
After-hours: Dec 29, 2023, 7:57 PM EST
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Adial Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Cary John Claiborne MBA |
Contact Details
Address: 1180 Seminole Trail, Suite 495 Charlottesville, Virginia 22901 United States | |
| Phone | 434-422-9800 |
| Website | adialpharma.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A106 |
| ISIN Number | US00688A2050 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President and Director |
| Joseph A. M. Truluck M.B.A., MBA | Chief Financial Officer, Treasurer and Secretary |
| Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. | Founder and Chief Medical Officer |
| John R. Martin J.D. | General Counsel |
| Alex Lugovoy | Chief Business Officer |
| Dr. Jack W. Reich Ph.D. | Head of Regulatory |
| Mark H. Peikin | Chief Strategy Officer and Chief Development Officer |
| Lawrence Goldman CPA | Controller |
| Catherine Fratila | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 15, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 12, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 8, 2023 | DEF 14A | Other definitive proxy statements |
| Nov 29, 2023 | 8-K | Current Report |
| Nov 28, 2023 | 8-K | Current Report |
| Nov 24, 2023 | PRE 14A | Other preliminary proxy statements |
| Nov 20, 2023 | 424B3 | Prospectus |
| Nov 16, 2023 | EFFECT | Notice of Effectiveness |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |